Artelo Files Patent for ART27.13 in Obesity
SOLANA BEACH, Calif. — September 23, 2026 Artelo Biosciences announced that it has filed a new provisional patent application...
Glaucoma
Advertisement
InxMed Reports Positive Phase Ib/II Data for Ifebemtinib
NANJING, China, Aug 28, 2026 InxMed Co., Ltd. announced the publication in The Lancet Oncology of clinical results evaluating...
Lilly’s Mounjaro Gains FDA Approval for Heart Risk Reduction
INDIANAPOLIS, U.S., Aug 28, 2026 Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has...
Nicox Sets April 2027 FDA Decision Date for NCX 470
SOPHIA ANTIPOLIS, FRANCE, Aug 27, 2026 Nicox SA announced that the U.S. Food and Drug Administration (FDA) has accepted...
Ingenia Therapeutics Goes Public to Accelerate Vascular Therapies
BOSTON, Massachusetts, and Seoul, South Korea — August 18, 2026 Ingenia Therapeutics announced that its shares have begun trading...
Advertisements
Artelo Biosciences Secures U.S. Patent Allowance for ART27.13
Solana Beach, California — August 17, 2026 Artelo Biosciences, Inc. announced that the U.S. Patent and Trademark Office (USPTO)...
Artelo Biosciences Starts Phase 2 Glaucoma Trial
SOLANA BEACH, Calif., August 10, 2026 Artelo Biosciences, Inc. announced that the first patient has been dosed in the...
Glaukos Completes Enrollment in PRESERFLO MicroShunt Pivotal Study
Aliso Viejo, California, July 27, 2026 Glaukos Corporation announced the completion of patient enrollment in its U.S. 510(k) pivotal...
Nona Biosciences Appoints Josh Xiao as New CSO
CAMBRIDGE, Mass., May 6, 2026 Nona Biosciences, a global biotechnology company specializing in biotherapeutic discovery and AI-driven drug development...
Bayer to Acquire Perfuse Therapeutics in $2.45B Deal
BERLIN, Germany, and SAN FRANCISCO, Calif., May 6, 2026 Bayer has announced an agreement to fully acquire Perfuse Therapeutics...
Advertisement
